Back to search
FDAFDA · Food and drugs·Recall number D-0632-2017

Adalat CC (nifedipine) Extended-Release Tablets, 90 mg, 100-count bottles, Rx Only, Manufactured for Almatica Pharma Inc. Pine Brook, NJ 07058 USA, NDC 50419-70305

Published April 12, 2017 · Recall initiated: March 7, 2017

Summary

FDA records drug Class III recall D-0632-2017, published April 12, 2017 and initiated March 7, 2017. Recalling firm: Alvogen, Inc; Status: Terminated; Reported quantity: N/A; Lot: Lot #: BXH66D1A, Exp. 03/2018. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Alvogen, Inc
Distributor
Nationwide
Lot
Lot #: BXH66D1A, Exp. 03/2018
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Adalat CC (nifedipine) Extended-Release Tablets, 90 mg, 100-count bottles, Rx Only, Manufactured for Almatica Pharma Inc. Pine Brook, NJ 07058 USA, NDC 50419-70305 recalled?

Yes. FDA published recall D-0632-2017 on April 12, 2017. Reported hazard: Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

What should I do if I have this product?

Voluntary: Firm initiated · Letter